I-Mab (NASDAQ: IMAB) is a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer. I-Mab has established operations in the U.S.

Broadleaf Partners Growth Equity Portfolio returned -11.6% for Q1 2025 vs. the S&P 500 -4.3% return. Click here to read the ...

Just under half of U.S. employees who participated in a Gallup survey “strongly agreed” that they know what is expected of them at work.

The pandemic has left many workers unclear about job expectations ... Managers and employees have bushwhacked their way through disruptive changes since COVID-19 first upended public life five ...

Revenue expectations were also revised, now projected to be flat or slightly down year-over-year, compared to prior guidance of approximately flat. The results reflect ongoing freight market ...

Today is Nowruz. It marks the coming of the new year in some cultures. But what is Nowruz, and why do people celebrate it? Thursday, March 20, 2025, marks the Persian New Year, or Nowruz ...

“Really pleased with first-half performance – slightly ahead of expectations coming into the year, good confidence heading into the second half. Market conditions not really changed – still ...

The tables have turned for tech employees as performance pressure and proclamations of "efficiency" and "intensity" replace ...